VANCOUVER, BC / ACCESSWIRE / August 10, 2021 / Gemina Laboratories Ltd. (CSE:GLAB) (the “Company” or “Gemina“) is pleased to announce that the common shares of the Company have begun trading on the Canadian Securities Exchange (the “CSE”) at the open of trading on August 10, 2021 under the trading symbol “GLAB.”
Gemina Labs is an innovative biosensor and diagnostic company working to revolutionize health and wellness testing using patented biochemistry with significantly improved performance. With a globally successful team at the helm, Gemina is creating highly accurate tests that are both affordable and convenient for consumers and medical practitioners alike, with results delivered in just 5-10 minutes. To democratize diagnostic testing, the company aims to deliver testing at the point of need. Gemina Labs is addressing a wide range of pathogens affecting both human and animal health and wellness, including COVID-19, influenza, and other viruses and conditions. To learn more about the company’s groundbreaking work, explore its website.
In conjunction with the public listing, the Company has closed its non-brokered private placement of $2,406,500 sold at an offering price of $0.30 per unit. Each unit consists of one common share in the capital of the Company and one half of one common share purchase-warrant. Each warrant entitles the holder to acquire one additional Common Share of the Company at an exercise price of $0.45 at any time within three years from the closing date of the private placement. The Company has raised a total of $4,271,500 to date, inclusive of $990,000 of non-dilutive funding received from the Federal Digital Supercluster and partners.
Additional information on the Company can be found in the Company’s final prospectus dated July 28, 2021, as filed under the Company’s profile on SEDAR at www.sedar.com.
On Behalf of the Board of Directors
John Davies
CEO
Gemina Laboratories Ltd
About Gemina Laboratories Ltd.
Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary biochemistry that powers next-generation testing platforms for a wide range of pathogens that affect both humans and animal health and wellness. Our technology drives testing platforms that are fast, affordable, and accurate, and are easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.
